CYTEK BIOSCIENCES INC (CTKB)
US23285D1090 - Common Stock
Overall CTKB gets a fundamental rating of 5 out of 10. We evaluated CTKB against 55 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for CTKB as it has an excellent financial health rating, but there are worries on the profitability. CTKB is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CTKB had negative earnings in the past year.
CTKB had a positive operating cash flow in the past year.
In multiple years CTKB reported negative net income over the last 5 years.
In multiple years CTKB reported negative operating cash flow during the last 5 years.
1.2 Ratios
CTKB's Return On Assets of -3.63% is fine compared to the rest of the industry. CTKB outperforms 63.64% of its industry peers.
CTKB's Return On Equity of -4.51% is fine compared to the rest of the industry. CTKB outperforms 65.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.63% | ||
| ROE | -4.51% | ||
| ROIC | N/A |
ROA(3y)-0.65%
ROA(5y)-4.87%
ROE(3y)-0.83%
ROE(5y)-10.32%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 54.97%, CTKB is doing good in the industry, outperforming 70.91% of the companies in the same industry.
In the last couple of years the Gross Margin of CTKB has remained more or less at the same level.
CTKB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.58%
GM growth 5YN/A
2. Health
2.1 Basic Checks
CTKB does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTKB has less shares outstanding than it did 1 year ago.
The debt/assets ratio for CTKB has been reduced compared to a year ago.
2.2 Solvency
CTKB has an Altman-Z score of 5.93. This indicates that CTKB is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.93, CTKB belongs to the best of the industry, outperforming 83.64% of the companies in the same industry.
The Debt to FCF ratio of CTKB is 0.31, which is an excellent value as it means it would take CTKB, only 0.31 years of fcf income to pay off all of its debts.
CTKB has a Debt to FCF ratio of 0.31. This is amongst the best in the industry. CTKB outperforms 92.73% of its industry peers.
CTKB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, CTKB is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.31 | ||
| Altman-Z | 5.93 |
ROIC/WACCN/A
WACC11.25%
2.3 Liquidity
A Current Ratio of 7.33 indicates that CTKB has no problem at all paying its short term obligations.
CTKB has a Current ratio of 7.33. This is amongst the best in the industry. CTKB outperforms 83.64% of its industry peers.
CTKB has a Quick Ratio of 6.38. This indicates that CTKB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 6.38, CTKB belongs to the best of the industry, outperforming 83.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.33 | ||
| Quick Ratio | 6.38 |
3. Growth
3.1 Past
The earnings per share for CTKB have decreased strongly by -215.94% in the last year.
Looking at the last year, CTKB shows a quite strong growth in Revenue. The Revenue has grown by 9.88% in the last year.
The Revenue has been growing by 27.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-215.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1100%
Revenue 1Y (TTM)9.88%
Revenue growth 3Y27.65%
Revenue growth 5YN/A
Sales Q2Q%7.29%
3.2 Future
Based on estimates for the next years, CTKB will show a very strong growth in Earnings Per Share. The EPS will grow by 29.78% on average per year.
CTKB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.27% yearly.
EPS Next Y-266.53%
EPS Next 2Y22.42%
EPS Next 3Y29.78%
EPS Next 5YN/A
Revenue Next Year6.9%
Revenue Next 2Y10.79%
Revenue Next 3Y11.27%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
CTKB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 87.96, CTKB can be considered very expensive at the moment.
The rest of the industry has a similar Price/Forward Earnings ratio as CTKB.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.82, CTKB is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 87.96 |
4.2 Price Multiples
CTKB's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 78.12 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CTKB's earnings are expected to grow with 29.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.42%
EPS Next 3Y29.78%
5. Dividend
5.1 Amount
CTKB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYTEK BIOSCIENCES INC
NASDAQ:CTKB (11/21/2024, 8:21:25 PM)
After market: 6.49 +0.03 (+0.46%)6.46
+0.33 (+5.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap832.11M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 87.96 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.63% | ||
| ROE | -4.51% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.97% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.33 | ||
| Quick Ratio | 6.38 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-215.94%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-266.53%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)9.88%
Revenue growth 3Y27.65%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y